Wall Street brokerages expect that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will report earnings per share of ($0.53) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Cellular Biomedicine Group’s earnings, with estimates ranging from ($0.55) to ($0.50). Cellular Biomedicine Group also reported earnings per share of ($0.53) in the same quarter last year. The company is expected to report its next earnings report on Wednesday, August 14th.
On average, analysts expect that Cellular Biomedicine Group will report full-year earnings of ($2.09) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($1.90). For the next year, analysts anticipate that the company will post earnings of ($1.97) per share. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Cellular Biomedicine Group.
Cellular Biomedicine Group (NASDAQ:CBMG) last announced its earnings results on Tuesday, April 30th. The biotechnology company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.06. The firm had revenue of $0.05 million for the quarter. Cellular Biomedicine Group had a negative net margin of 17,921.62% and a negative return on equity of 42.41%.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA grew its position in Cellular Biomedicine Group by 1,641.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 2,315 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in Cellular Biomedicine Group in the 4th quarter worth $81,000. Rhumbline Advisers grew its position in Cellular Biomedicine Group by 49.2% in the 4th quarter. Rhumbline Advisers now owns 15,377 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 5,074 shares during the last quarter. Bank of New York Mellon Corp grew its position in Cellular Biomedicine Group by 16.3% in the 4th quarter. Bank of New York Mellon Corp now owns 37,857 shares of the biotechnology company’s stock worth $669,000 after purchasing an additional 5,308 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in Cellular Biomedicine Group in the 4th quarter worth $110,000. Institutional investors own 18.99% of the company’s stock.
Shares of CBMG opened at $14.55 on Friday. Cellular Biomedicine Group has a one year low of $12.04 and a one year high of $25.00. The stock has a fifty day moving average price of $15.92.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.
See Also: What is a Reverse Stock Split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.